In this iteration of SSO‐QPOP, we selected four SSOs against MYC synthetic lethal targets (CHEK1, MAX, MCL1, and BRD4) with the greatest knockdown efficiencies amongst a panel of eight targets, together with two HCC standard‐of‐care drugs, sorafenib and cabozantinib to compare the efficacy of targeting MYC synthetic lethality with the standard‐of‐care drugs.65, 66. The gene discussed is MYC; the disease is hepatocellular carcinoma.